201 related articles for article (PubMed ID: 23771415)
1. Apocrine carcinoma of the breast: a comprehensive review.
Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
4. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast.
Vranic S; Tawfik O; Palazzo J; Bilalovic N; Eyzaguirre E; Lee LM; Adegboyega P; Hagenkord J; Gatalica Z
Mod Pathol; 2010 May; 23(5):644-53. PubMed ID: 20208479
[TBL] [Abstract][Full Text] [Related]
5. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
D'Arcy C; Quinn CM
J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous metastases from breast carcinoma: calretinin expression and estrogen, progesterone and Her2/neu status of the metastases, compared to primary cutaneous apocrine tumors.
Fernandez-Flores A
Rom J Morphol Embryol; 2013; 54(3 Suppl):695-9. PubMed ID: 24322014
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
8. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
Schmitt FC; Soares R; Seruca R
Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
[TBL] [Abstract][Full Text] [Related]
9. The role of histopathologic testing on apocrine carcinoma of the breast.
Ilhan B; Emiroğlu S; Türkay R; Ilhan R
Curr Probl Cancer; 2020 Apr; 44(2):100501. PubMed ID: 31521370
[TBL] [Abstract][Full Text] [Related]
10. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
[TBL] [Abstract][Full Text] [Related]
11. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
Vranic S; Gatalica Z
Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
[TBL] [Abstract][Full Text] [Related]
14. The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.
Kővári B; Vranic S; Marchio C; Sapino A; Cserni G
Hum Pathol; 2017 Jun; 64():164-170. PubMed ID: 28438614
[TBL] [Abstract][Full Text] [Related]
15. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
[TBL] [Abstract][Full Text] [Related]
17. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
19. Cystic apocrine ductal carcinoma in situ with increased EGFR expression, trisomy 7, and associated focal invasion.
Tajima S; Waki M; Nasu H; Ide Y
Med Mol Morphol; 2016 Sep; 49(3):170-6. PubMed ID: 25374127
[TBL] [Abstract][Full Text] [Related]
20. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses.
Le LP; Dias-Santagata D; Pawlak AC; Cosper AK; Nguyen AT; Selim MA; Deng A; Horick NK; Iafrate AJ; Mihm MC; Hoang MP
PLoS One; 2012; 7(10):e47290. PubMed ID: 23056620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
